CYTX - Plus Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2077
-0.0064 (-2.99%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2141
Open0.2265
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.2043 - 0.2265
52 Week Range0.1310 - 0.5120
Volume444,450
Avg. Volume683,026
Market Cap4.602M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateApr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    Cytori Will Become Plus Therapeutics, Inc.

    Cytori Therapeutics, Inc. (CYTX) (the “company”) announced yesterday a new direction and identity. Since the beginning of 2019, the company has successfully evaluated and transformed its pipeline to place a stronger emphasis on product candidates that can maximize returns for shareholders and make a clinically meaningful impact for patients. Plus Therapeutics, Inc. plans to create and realize this value by developing drugs for niche and orphan markets, initially in oncology, that address significant unmet or substantially underserved medical needs and that represent global revenue opportunities estimated to be $250 million or more.

  • Should You Worry About Cytori Therapeutics, Inc.'s (NASDAQ:CYTX) CEO Pay Cheque?
    Simply Wall St.

    Should You Worry About Cytori Therapeutics, Inc.'s (NASDAQ:CYTX) CEO Pay Cheque?

    Marc Hedrick became the CEO of Cytori Therapeutics, Inc. (NASDAQ:CYTX) in 2014. First, this article will compare CEO...

  • GlobeNewswire

    Cytori to Present Corporate Update & New Strategic Direction

    SAN DIEGO, July 11, 2019 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its new company direction following two recent asset.

  • Benzinga

    Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug

    Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX ), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement ...

  • GlobeNewswire

    Cytori Reports Summary of FDA Feedback Regarding its ATI-1123 Product

    Cytori Therapeutics, Inc. (CYTX) today provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA). ATI-1123 is a substantially redesigned and reformulated new drug based in part, on the active pharmaceutical ingredient, docetaxel. The purpose of the Company’s submission was to clarify certain key aspects of the future development plan including: (1) the suitability of the 505(b)(2) pathway for approval of the proposed ATI-1123 drug product, including the proposed listed drug (LD), (2) the adequacy of the referenced clinical, nonclinical and pharmaceutical quality information, in combination with the proposed drug development program, to support the new drug application and (3) any concerns that the FDA may have with regard to other filing issues specific to the product.

  • GlobeNewswire

    Cytori Announces New Annual Stockholders Meeting Date for July 11

    Cytori Therapeutics, Inc. (CYTX) today announced that it reconvened its annual meeting of stockholders on Thursday, June 27, 2019 and adjourned the meeting until Thursday, July 11, 2019, at 9:00 a.m., Central Time. The annual meeting was adjourned to allow the Company’s stockholders an additional opportunity to evaluate Proposal 4, relating to the approval of a reverse stock split of the Company’s common stock.  Although more than 69% of the votes cast were in favor of the reverse stock split (Proposal 4), this constitutes approximately 48% of the Company’s outstanding shares of common stock and approval requires the affirmative vote of a majority of the outstanding shares of common stock. The annual meeting was adjourned until 9:00 a.m., Central Time, on July 11, 2019 at 4200 Marathon Blvd., Suite 200, Austin Texas 78756, the Company’s offices in Austin, Texas.

  • GlobeNewswire

    Cytori Announces New Annual Stockholders Meeting Date for June 27

    SAN DIEGO, June 19, 2019 -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeting of stockholders on Tuesday, June 18, 2019 and.

  • GlobeNewswire

    Cytori to Present New Strategic Direction

    SAN DIEGO, June 13, 2019 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its continued transformation efforts following two.

  • GlobeNewswire

    Cytori Announces New Annual Stockholders Meeting Date for June 18

    Cytori Therapeutics, Inc. (CYTX) today announced that it convened its annual meeting of stockholders on Tuesday, May 28, 2019 and adjourned the meeting until Tuesday, June 18, 2019, at 9:00 a.m., Pacific Time. The annual meeting was adjourned to allow the Company’s stockholders an additional opportunity to evaluate Proposal 4, relating to the approval of a reverse stock split of the Company’s common stock.  Although more than 64% of the votes cast were in favor of the reverse stock split (Proposal 4), approval requires the affirmative vote of a majority of the outstanding shares of common stock. Stockholders that have yet to vote are requested to do so prior to the new June 18 meeting date and are encouraged to vote in favor of the reverse stock split as outlined in the Company’s proxy materials.

  • Associated Press

    Cytori: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 18 cents per share. The developer of cell therapies posted revenue of $703,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • GlobeNewswire

    Cytori Reports Q1 2019 Business and Financial Results

    SAN DIEGO, May 14, 2019 -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced Q1 2019 financial results and provided updates on corporate.

  • GlobeNewswire

    Japan Cell Therapy Transaction Yields $3MM

    Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced a transaction to divest certain cell therapy assets to Seijirō Shirahama of Tokyo, Japan yielding $3MM in non-dilutive funding to the Company, before related transaction expenses. “This cell therapy asset sale strengthens the company’s ability to achieve a number of important objectives including – enabling us to focus on our clinical stage oncology pipeline while bringing in additional non-dilutive capital,” said Dr. Marc Hedrick, Cytori President & Chief Executive Officer. This announcement follows an April 1, 2019 announcement stating that Cytori was to divest certain cell therapy assets to Lorem Vascular of Melbourne, Australia yielding $4MM in non-dilutive funding to the Company, before related transaction expenses.

  • Thomson Reuters StreetEvents

    Edited Transcript of CYTX earnings conference call or presentation 1-Apr-19 12:30pm GMT

    Q4 2018 Cytori Therapeutics Inc Earnings Call

  • Analysts Expect Breakeven For Cytori Therapeutics, Inc. (NASDAQ:CYTX)
    Simply Wall St.

    Analysts Expect Breakeven For Cytori Therapeutics, Inc. (NASDAQ:CYTX)

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Cytori Therapeutics, Inc.'s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidi...

  • Associated Press

    Cytori: 4Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 16 cents. Losses, adjusted for non-recurring gains, came to 20 cents per share. The developer of cell therapies posted revenue of ...

  • GlobeNewswire

    Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results

    Strategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM Letter of intent for ATI-0918 filed with EMEA.

  • GlobeNewswire

    Cytori to Webcast Fourth Quarter and 2018 Financial Results on April 1

    SAN DIEGO, March 29, 2019 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year-end financial results and business update on.

  • GlobeNewswire

    Cytori Files Pre-submission Request for New Drug Application

    Cytori Therapeutics, Inc. (CYTX) today announced that it officially filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the precursor to filing an Article 58 Application for a Marketing Authorization Application (MAA) via EMA’s centralized approval procedure. In addition, in late 2018, the EMA CHMP Name Review Group validated Doxorubicin Hydrochloride Cytori as the official invented name to replace ATI-0918.  Doxorubicin Hydrochloride Cytori is a liposomal nanoparticle medicinal product being developed for cancer patients that contains the active substance doxorubicin, a widely used chemotherapy drug.  Doxorubicin Hydrochloride Cytori is intended for the treatment of breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma.

  • GlobeNewswire

    Cytori Cell Therapy™ Clinical Trial Results in Crohn’s Disease

    Cytori Therapeutics, Inc. (CYTX) announces the publication of results from a pilot investigator-initiated clinical trial of Cytori Cell Therapy™ for the treatment of refractory perianal fistula in patients with Crohn’s Disease. 10 patients were treated with a single administration of Cytori Cell Therapy™.

  • Does Cytori Therapeutics, Inc. (NASDAQ:CYTX) Have A High Beta?
    Simply Wall St.

    Does Cytori Therapeutics, Inc. (NASDAQ:CYTX) Have A High Beta?

    If you own shares in Cytori Therapeutics, Inc. (NASDAQ:CYTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Thomson Reuters StreetEvents

    Edited Transcript of CYTX earnings conference call or presentation 14-Nov-18 10:30pm GMT

    Q3 2018 Cytori Therapeutics Inc Earnings Call

  • Benzinga

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...

  • Benzinga

    Shares Of Penny Stock Cytori Rise On Japanese Device Approval

    Cytori announced it has received approval for its Cellution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Cellution Cell Therapy System is a medical device designed to automate processing of adipose tissue to obtain regenerative cells suitable for treating thermal and radioactive burn wounds.

  • GlobeNewswire

    Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product

    Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval for the Celution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Class III designation will allow Cytori to expand its current commercial efforts in Japan and provides a clear framework for future expanded regulatory claims and reimbursement under the November 2014 PMD Act. Furthermore, Cytori announced today that the Company has successfully outsourced an important assembly portion of the production process for its Celution Cell Therapy consumables from San Diego, CA to Viant Medical in San Antonio, Texas.

  • Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates

    Cytori (CYTX) delivered earnings and revenue surprises of -246.15% and -59.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?